Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Martin Griesshammer, MD, Alessandro M. Vannucchi, MD, Philipp le Coutre, MD, Renato S Tavares, MD, Haifa Kathrin Al-Ali, MD, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Pilar Giraldo, Catherine Bouard, Julian Perez Ronco, MD MBA, Jagannath Ghosh, Bruno Martino, MD

Blood (2014) 124 (21): 1859.

https://doi.org/10.1182/blood.V124.21.1859.1859

Published: 2014

Journal Articles

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Haifa Kathrin Al-Ali, MD, Viktoriya Stalbovskaya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Julian Perez Ronco, MD MBA, Lynda M Foltz, MD FRCP

Blood (2014) 124 (21): 4583.

https://doi.org/10.1182/blood.V124.21.4583.4583

Published: 2014

Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 714.

https://doi.org/10.1182/blood.V124.21.714.714

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Renato S Tavares, MD, Martin Griesshammer, MD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Pilar Giraldo, Haifa Kathrin Al-Ali, MD, Bruno Martino, MD, Bayane Tannir, Julian Perez Ronco, MD, Jagannath Ghosh, Alessandro M. Vannucchi, MD

Blood (2014) 124 (21): 5567.

https://doi.org/10.1182/blood.V124.21.5567.5567

Published: 2014

Journal Articles

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Bruno Martino, Philipp le Coutre, MD, Martin Griesshammer, MD, Thomas Illmer, MD, Rudolf Schlag, Cornelius F. Waller, MD, Anna Marina Liberati, Philippe Schafhausen, MD, Renato S Tavares, MD, Alessandro M. Vannucchi, MD, Pilar Giraldo, MD PhD, Lynda M Foltz, MD FRCP, Pia Raanani, MD, Vikas Gupta, MD FRCP, FRCPath, Bayane Tannir, Julian Perez Ronco, MD, Jaggannath Ghosh, Haifa Kathrin Al-Ali, MD

Blood (2014) 124 (21): 3197.

https://doi.org/10.1182/blood.V124.21.3197.3197

Published: 2014

Journal Articles

Barriers To Diagnosis In Myeloproliferative Neoplasms

Raymond H L Yip, Lynda M Foltz, MD, FRCP(C)

Blood (2013) 122 (21): 5248.

https://doi.org/10.1182/blood.V122.21.5248.5248

Published: 2013

Journal Articles

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Heather A Leitch, MD, PhD, FRCPC, Christopher Chan, Chantal S Leger, MD, FRCP(C), Lynda M Foltz, MD, FRCP(C), Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Linda M Vickars, MD, FRCP(C)

Blood (2011) 118 (21): 1732.

https://doi.org/10.1182/blood.V118.21.1732.1732

Published: 2011

Journal Articles

Clinical Features, Treatment, and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura In the HAART Era

Kimberley LS Ambler, MD, FRCP(C), Linda M Vickars, MD, FRCP(C), Chantal S Leger, MD, FRCP(C), Lynda M Foltz, MD, FRCP(C), Julio SG Montaner, MD, FRCPC, FCCP, Marianne Harris, MD, FRCPC, Heather A Leitch, MD, PhD, FRCP(C)

Blood (2010) 116 (21): 2522.

https://doi.org/10.1182/blood.V116.21.2522.2522

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and Efficacy of Ruxolitinib in Patients with Low Platelets Enrolled in a Phase 3b Expanded-Access Study in Myelofibrosis (MF)

Ruxolitinib Overcomes the Adverse Prognostic Effect of Anemia in Patients with Myelofibrosis (MF)

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

Safety and Efficacy of Ruxolitinib Retreatment after Treatment Interruption in Patients Enrolled in an Open-Label, Multicenter, Expanded-Access Study in Myelofibrosis

Safety and Efficacy of Ruxolitinib in an Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (MF): An 1144-Patient Update

Barriers To Diagnosis In Myeloproliferative Neoplasms

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Clinical Features, Treatment, and Outcome of Severe HIV-Associated Immune Thrombocytopenic Purpura In the HAART Era

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only